Point72 Asset Management L.P. Boosts Stake in TherapeuticsMD Inc (TXMD)

Point72 Asset Management L.P. boosted its stake in shares of TherapeuticsMD Inc (NASDAQ:TXMD) by 45.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 296,700 shares of the company’s stock after buying an additional 93,400 shares during the period. Point72 Asset Management L.P.’s holdings in TherapeuticsMD were worth $2,136,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Raymond James Financial Services Advisors Inc. increased its stake in TherapeuticsMD by 56.1% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 28,730 shares of the company’s stock valued at $207,000 after buying an additional 10,330 shares during the last quarter. Greenwood Capital Associates LLC increased its stake in TherapeuticsMD by 17.5% in the first quarter. Greenwood Capital Associates LLC now owns 20,309 shares of the company’s stock valued at $146,000 after buying an additional 3,022 shares during the last quarter. JPMorgan Chase & Co. increased its stake in TherapeuticsMD by 2.5% in the first quarter. JPMorgan Chase & Co. now owns 13,725,853 shares of the company’s stock valued at $98,827,000 after buying an additional 329,245 shares during the last quarter. Stifel Financial Corp increased its stake in TherapeuticsMD by 125.4% in the first quarter. Stifel Financial Corp now owns 429,362 shares of the company’s stock valued at $3,091,000 after buying an additional 238,885 shares during the last quarter. Finally, American International Group Inc. increased its stake in TherapeuticsMD by 7.1% in the first quarter. American International Group Inc. now owns 92,415 shares of the company’s stock valued at $665,000 after buying an additional 6,103 shares during the last quarter.

TherapeuticsMD Inc (NASDAQ:TXMD) opened at 5.01 on Monday. The firm has a 50-day moving average of $4.62 and a 200-day moving average of $5.62. TherapeuticsMD Inc has a one year low of $3.50 and a one year high of $8.39. The company’s market capitalization is $1.02 billion.

TRADEMARK VIOLATION WARNING: This report was originally published by WKRB News and is owned by of WKRB News. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.wkrb13.com/markets/2285031/point72-asset-management-l-p-boosts-stake-in-therapeuticsmd-inc-txmd.html.

Several analysts recently weighed in on TXMD shares. Oppenheimer Holdings, Inc. restated an “outperform” rating and issued a $15.00 price objective on shares of TherapeuticsMD in a report on Monday, April 17th. Stifel Nicolaus restated a “buy” rating and issued a $20.00 price objective on shares of TherapeuticsMD in a report on Monday, April 24th. Zacks Investment Research downgraded TherapeuticsMD from a “hold” rating to a “sell” rating in a report on Wednesday, May 3rd. CIBC restated a “market perform” rating and issued a $12.00 price objective on shares of TherapeuticsMD in a report on Tuesday, May 9th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $33.00 price objective on shares of TherapeuticsMD in a report on Wednesday, May 10th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. TherapeuticsMD currently has a consensus rating of “Buy” and an average price target of $18.40.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Want to see what other hedge funds are holding TXMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TherapeuticsMD Inc (NASDAQ:TXMD).

Institutional Ownership by Quarter for TherapeuticsMD (NASDAQ:TXMD)

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2285031/point72-asset-management-l-p-boosts-stake-in-therapeuticsmd-inc-txmd.html

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.